重度主动脉瓣狭窄患者心肌瘢痕与死亡率的关系
结果显示51%患者存在瘢痕,瘢痕独立预测全因死亡(HR 2.39)和心血管死亡,且每增加1%瘢痕负荷,全因死亡风险增加11%。
要点
- 重度主动脉瓣狭窄患者中51%存在心肌瘢痕(18%梗死型,33%非梗死型)。
- 瘢痕存在使全因死亡风险增加约2倍(HR 2.39),独立于年龄和STS评分。
- 每1%左室心肌瘢痕负荷增加,全因死亡风险增加11%。
核心结论
- 在重度主动脉瓣狭窄患者中,心脏磁共振晚期钆增强提示的心肌瘢痕与全因死亡和心血管死亡独立相关。
研究设计与样本
- 患者术前接受超声心动图评估瓣膜严重程度和心脏磁共振评估心室容积、功能及瘢痕定量,随访至少2年。
主要发现
- 瘢痕存在于51%患者中(18%梗死型,33%非梗死型);中位随访3.6年期间145例(21.5%)死亡(外科AVR后52例,经导管AVR后93例)。
- 多变量分析中,全因死亡的独立相关因素包括年龄(HR 1.50;95% CI 1.11-2.04;P=0.009,按10年分期)、STS评分(HR 1.12;95% CI 1.03-1.22;P=0.007)和瘢痕存在(HR 2.39;95% CI 1.40-4.05;P=0.001)。
- 瘢痕独立预测全因死亡(26.4% vs 12.9%;P<0.001)和心血管死亡(15.0% vs 4.8%;P<0.001),无论干预方式(经导管AVR全因死亡P=0.002;外科AVR全因死亡P=0.026)。
- 左室心肌瘢痕负荷每增加1%,全因死亡风险增加11%(HR 1.11;95% CI 1.05-1.17;P<0.001),心血管死亡风险增加8%(HR 1.08;95% CI 1.01-1.17;P<0.001)。
临床怎么用
- 对于重度主动脉瓣狭窄患者,术前心脏磁共振检测心肌瘢痕可帮助识别长期死亡风险较高的患者。
- 心肌瘢痕的存在和负荷程度可能有助于优化瓣膜干预时机和术后管理决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aortic valve replacement (AVR) for aortic stenosis is timed primarily on the development of symptoms, but late surgery can result in irreversible myocardial dysfunction and additional risk. The aim of this study was to determine whether the presence of focal myocardial scar preoperatively was associated with long-term mortality. METHODS: In a longitudinal observational outcome study, survival analysis was performed in patients with severe aortic stenosis listed for valve intervention at 6 UK cardiothoracic centers. Patients underwent preprocedural echocardiography (for valve severity assessment) and cardiovascular magnetic resonance for ventricular volumes, function and scar quantification between January 2003 and May 2015. Myocardial scar was categorized into 3 patterns (none, infarct, or noninfarct patterns) and quantified with the full width at half-maximum method as percentage of the left ventricle. All-cause mortality and cardiovascular mortality were tracked for a minimum of 2 years. RESULTS: Six hundred seventy-four patients with severe aortic stenosis (age, 75±14 years; 63% male; aortic valve area, 0.38±0.14 cm2/m2; mean gradient, 46±18 mm Hg; left ventricular ejection fraction, 61.0±16.7%) were included. Scar was present in 51% (18% infarct pattern, 33% noninfarct). Management was surgical AVR (n=399) or transcatheter AVR (n=275). During follow-up (median, 3.6 years), 145 patients (21.5%) died (52 after surgical AVR, 93 after transcatheter AVR). In multivariable analysis, the factors independently associated with all-cause mortality were age (hazard ratio [HR], 1.50; 95% CI, 1.11-2.04; P=0.009, scaled by epochs of 10 years), Society of Thoracic Surgeons score (HR, 1.12; 95% CI, 1.03-1.22; P=0.007), and scar presence (HR, 2.39; 95% CI, 1.40-4.05; P=0.001). Scar independently predicted all-cause (26.4% versus 12.9%; P<0.001) and cardiovascular (15.0% versus 4.8%; P<0.001) mortality, regardless of intervention (transcatheter AVR, P=0.002; surgical AVR, P=0.026 [all-cause mortality]). Every 1% increase in left ventricular myocardial scar burden was associated with 11% higher all-cause mortality hazard (HR, 1.11; 95% CI, 1.05-1.17; P<0.001) and 8% higher cardiovascular mortality hazard (HR, 1.08; 95% CI, 1.01-1.17; P<0.001). CONCLUSIONS: In patients with severe aortic stenosis, late gadolinium enhancement on cardiovascular magnetic resonance was independently associated with mortality; its presence was associated with a 2-fold higher late mortality.
引用
- Musa TA, Treibel TA, Vassiliou VS, et al. Myocardial Scar and Mortality in Severe Aortic Stenosis. Circulation. 2018. PMID: 30002099. doi:10.1161/CIRCULATIONAHA.117.032839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。